Physician profile
Michael A Dorman
NPI 1841281532
$433,271.78
in general payments reported to CMS, 2019-2025
46 companies · $113K in 2025
The $113K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $23K · 2021: $23K · 2022: $57K · 2023: $89K · 2024: $96K · 2025: $113K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $199K · Consulting Fee: $39K · Food and Beverage: $21K · Travel and Lodging: $18K · Honoraria: $15K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $6,000 · Education: $294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $198,505.00 |
| Consulting Fee | $38,735.00 |
| Food and Beverage | $20,904.67 |
| Travel and Lodging | $17,538.09 |
| Honoraria | $15,200.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $6,000.00 |
| Education | $294.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $102,719.42 | 2019-2025 | Aklief, Epsolay, Oracea |
| Dermavant Sciences, INC. | $64,688.40 | 2022-2024 | Vtama |
| Ucb, INC. | $49,745.53 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $49,011.02 | 2019-2025 | Tremfya, Simponi, Stelara |
| Arcutis Biotherapeutics, INC. | $40,059.97 | 2023-2025 | Zoryve |
| Janssen Scientific Affairs, LLC | $37,120.23 | 2021-2025 | Tremfya |
| Pfizer INC. | $19,852.18 | 2019-2025 | |
| Organon LLC | $16,961.04 | 2023-2025 | Vtama, Hadlima |
| Sun Pharmaceutical Industries INC. | $14,814.55 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Novartis Pharmaceuticals Corporation | $10,315.34 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $9,262.19 | 2019-2025 | Cabtreo, Jublia, Arazlo |
| Amgen INC. | $2,956.41 | 2019-2024 | Otezla, Enbrel, Amjevita |
| Galderma Research & Development, LLC | $2,677.50 | 2023 | |
| Abbvie INC. | $2,287.08 | 2019-2025 | Rinvoq, Skyrizi |
| Epi Health, LLC | $1,603.44 | 2021-2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dorman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.